CRESCENT BIOPHARMA, INC. Stockholders Equity

Quick Answer

CRESCENT BIOPHARMA, INC. reported Stockholders Equity of $203.01 million for the year ending 2025.

  • CRESCENT BIOPHARMA, INC. showed an increase of +1,411.5% in Stockholders Equity from 2024 to 2025.
  • This data is from CRESCENT BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2011 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q1 2014: $55.35 million | Q2 2014: $63.88 million | Q3 2014: $57.71 million | Q1 2015: $44.36 million | Q2 2015: $55.22 million | Q3 2015: $48.70 million | Q1 2016: $34.77 million | Q2 2016: $48.88 million | Q3 2016: $41.75 million | Q1 2017: $31.89 million | Q2 2017: $115.43 million | Q3 2017: $108.56 million | Q1 2018: $238.04 million | Q2 2018: $227.99 million | Q3 2018: $218.10 million | Q1 2019: $192.79 million | Q2 2019: $178.56 million | Q3 2019: $167.08 million | Q1 2020: $148.49 million | Q2 2020: $145.75 million | Q3 2020: $138.27 million | Q1 2021: $125.12 million | Q2 2021: $112.29 million | Q3 2021: $96.57 million | Q1 2022: $68.03 million | Q2 2022: $55.73 million | Q3 2022: $48.12 million | Q1 2023: $62.18 million | Q2 2023: $54.80 million | Q3 2023: $46.55 million | Q4 2023: $38.41 million | Q1 2024: $28.91 million | Q2 2024: $20.06 million | Q1 2025: -$30.16 million | Q2 2025: $139.25 million | Q3 2025: $116.64 million.
  • Over the full 16 years of available data (2011 to 2025), CRESCENT BIOPHARMA, INC.'s Stockholders Equity has grown by 2,300.5%.
  • Historical annual values: Fiscal year 2025: $203.01 million | Fiscal year 2024: -$15.48 million | Fiscal year 2024: $0.00 | Fiscal year 2023: $38.41 million | Fiscal year 2022: $42.93 million | Fiscal year 2021: $81.60 million | Fiscal year 2020: $128.22 million | Fiscal year 2019: $154.20 million | Fiscal year 2018: $205.46 million | Fiscal year 2017: $119.70 million | Fiscal year 2016: $35.30 million | Fiscal year 2015: $40.47 million | Fiscal year 2014: $50.80 million | Fiscal year 2013: $2.91 million | Fiscal year 2012: $12.53 million | Fiscal year 2011: $8.46 million.
  • Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: